ten23 health has changed the branding of its Visp, Switzerland based filling operation from swissfillon to ten23 health.
This represents a natural progression since the acquisition of swissfillon by ten23 health in October 2021 and is intended to unify the company’s operations under a single brand and to ease client communication and further strengthen the company’s growing global market position. This change also follows the completion of alignment of the company’s internal structure between the two sites Basel and Visp.
We are now gearing up as one team to meet the increasing market demand by providing customised expert solutions for our customers
The announcement follows the recent confirmation that ten23 health’s investment into two large-scale filling lines is on track. The initial phase of construction is complete. The expansion will add new sterile manufacturing lines using the latest isolator technology to ensure optimal sterility assurance levels for high value products.
“We are committed to building ten23 health into a leading global brand, synonymous with Swiss quality and services, focused on patients, people and planet,” said Hanns-Christian Mahler, CEO ten23 health. “Since the acquisition, the teams at Visp and Basel have been working tirelessly to establish a unique customer offering, integrating the pharmaceutical development and testing expertise in Basel with the sterile manufacturing excellence in Visp.”
Mahler continued: “With our sterile manufacturing expansions in Visp, we are now gearing up as one team to meet the increasing market demand by providing customised expert solutions for our customers and their patients globally.”
